Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2010 (2010), Article ID 320624, 12 pages
http://dx.doi.org/10.1155/2010/320624
Review Article

Impact of Autologous and Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphomas

Klinik für Hämatologie, Internistische Onkologie und Stammzelltransplantation, Kliniken Essen Süd, Evangelisches Krankenhaus Essen-Werden gGmbH, Pattbergstraβe 1-3, 45239 Essen, Germany

Received 25 August 2010; Revised 12 October 2010; Accepted 18 October 2010

Academic Editor: Brian Bolwell

Copyright © 2010 Peter Reimer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Peripheral T/NK-cell lymphomas (PTCLs) are rare malignancies characterized by poor prognosis. So far, no standard therapy has been established, due to the lack of randomised studies. High-dose therapy and autologous stem cell transplantation (HDT-autoSCT) have shown good feasibility with low toxicity in retrospective studies. In relapsing and refractory PTCL several comparison analyses suggest similar efficacy for PTCL when compared with aggressive B-cell lymphoma. In the upfront setting, prospective data show promising results with a long-lasting overall survival in a relevant subset of patients. Achieving a complete remission at transplantation seems to be the most important prognostic factor. Allogeneic stem cell transplantation (alloSCT) has been investigated only as salvage treatment. Especially when using reduced intensity conditioning regimen, eligible patients seem to benefit from this approach. To define the role for upfront stem cell transplantation a randomised trial by the German High-Grade Non-Hodgkin Lymphoma Study Group comparing HDT-autoSCT and alloSCT will be initiated this year.